BioSante merges with Cell Genesys

LINCOLNSHIRE - BioSante Pharmaceuticals Inc. and Cell Genesys announced that they have entered into a definitive agreement by which the companies will merge in an all-stock transaction, with BioSante as the surviving company. Upon completion of the transaction, BioSante stockholders before the merger are expected to own approximately 60.4 percent of the outstanding shares of the combined company and the former Cell Genesys stockholders are expected to own 39.6 percent.